Publication:
Darapladib for preventing ischemic events in stable coronary heart disease

Issued Date

2014-01-01

Resource Type

Article

ISSN

15334406
00284793

DOI

10.1056/NEJMoa1315878

Other identifier(s)

2-s2.0-84899718423

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

New England Journal of Medicine. Vol.370, No.18 (2014), 1702-1711

Suggested Citation

Harvey D. White, Claes Held, Ralph Stewart, Elizabeth Tarka, Rebekkah Brown, Richard Y. Davies, Andrzej Budaj, Robert A. Harrington, P. Gabriel Steg, Diego Ardissino, Paul W. Armstrong, Alvaro Avezum, Philip E. Aylward, Alfonso Bryce, Hong Chen, Ming Fong Chen, Ramon Corbalan, Anthony J. Dalby, Nicolas Danchin, Robbert J. De Winter, Stefan Denchev, Rafael Diaz, Moses Elisaf, Marcus D. Flather, Assen R. Goudev, Christopher B. Granger, Liliana Grinfeld, Judith S. Hochman, Steen Husted, Hyo Soo Kim, Wolfgang Koenig, Ales Linhart, Eva Lonn, José López-Sendón, Athanasios J. Manolis, Emile R. Mohler, José C. Nicolau, Prem Pais, Alexander Parkhomenko, Terje R. Pedersen, Daniel Pella, Marco A. Ramos-Corrales, Mikhail Ruda, Mátyás Sereg, Saulat Siddique, Peter Sinnaeve, Peter Smith, Piyamitr Sritara, Henk P. Swart, Rody G. Sy, Tamio Teramoto, Hung Fat Tse, David Watson, W. Douglas Weaver, Robert Weiss, Margus Viigimaa, Dragos Vinereanu, Junren Zhu, Christopher P. Cannon, Lars Wallentin Darapladib for preventing ischemic events in stable coronary heart disease. New England Journal of Medicine. Vol.370, No.18 (2014), 1702-1711. doi:10.1056/NEJMoa1315878 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/34884

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Darapladib for preventing ischemic events in stable coronary heart disease

Author(s)

Harvey D. White
 Claes Held
 Ralph Stewart
 Elizabeth Tarka
 Rebekkah Brown
 Richard Y. Davies
 Andrzej Budaj
 Robert A. Harrington
 P. Gabriel Steg
 Diego Ardissino
 Paul W. Armstrong
 Alvaro Avezum
 Philip E. Aylward
 Alfonso Bryce
 Hong Chen
 Ming Fong Chen
 Ramon Corbalan
 Anthony J. Dalby
 Nicolas Danchin
 Robbert J. De Winter
 Stefan Denchev
 Rafael Diaz
 Moses Elisaf
 Marcus D. Flather
 Assen R. Goudev
 Christopher B. Granger
 Liliana Grinfeld
 Judith S. Hochman
 Steen Husted
 Hyo Soo Kim
 Wolfgang Koenig
 Ales Linhart
 Eva Lonn
 José López-Sendón
 Athanasios J. Manolis
 Emile R. Mohler
 José C. Nicolau
 Prem Pais
 Alexander Parkhomenko
 Terje R. Pedersen
 Daniel Pella
 Marco A. Ramos-Corrales
 Mikhail Ruda
 Mátyás Sereg
 Saulat Siddique
 Peter Sinnaeve
 Peter Smith
 Piyamitr Sritara
 Henk P. Swart
 Rody G. Sy
 Tamio Teramoto
 Hung Fat Tse
 David Watson
 W. Douglas Weaver
 Robert Weiss
 Margus Viigimaa
 Dragos Vinereanu
 Junren Zhu
 Christopher P. Cannon
 Lars Wallentin

Other Contributor(s)

University of Auckland
 Akademiska Sjukhuset
 GlaxoSmithKline, USA
 Duke University Medical Center
 Szpital Grochowski, Warszawa
 Stanford University
 Inserm
 Universite Paris 7- Denis Diderot
 Universite Paris Descartes
 Royal Brompton Hospital
 Universita degli Studi di Parma
 University of Alberta
 McMaster University, Faculty of Health Sciences
 Instituto Dante Pazzanese de Cardiologia
 Instituto do Coracao do Hospital das Clinicas
 Flinders University
 Cardiogolf/Clinica El Golf
 Peking University
 National Taiwan University Hospital
 Pontificia Universidad Catolica de Chile
 Milpark Hospital
 Academic Medical Centre, University of Amsterdam
 University Hospital Alexandrovska
 Etudios Cardiologica Latin America, Rosario
 University of Ioannina, School of Medicine
 Norwich Medical School
 Norfolk and Norwich University Hospital NHS Trust
 Universidad de Buenos Aires
 NYU Langone Medical Center
 Hospital Unit West
 Seoul National University Hospital
 Universitat Ulm
 Veobecna Fakultni Nemocnice V Praze
 Charles University
 Hospital Universitario La Paz
 Asklepeion Hospital
 University of Pennsylvania
 St. Johns Medical College
 National Scientific Center M.D. Strazhesko Institute of Cardiology
 Universitetet i Oslo
 Pavol Jozef Safarik University in Kosice
 San Jose Satelite Hospital
 National Medical Research Center of Cardiology, Moscow
 St. George's Hospital
 Shaikh Zayed Postgraduate Medical Institute
 KU Leuven– University Hospital Leuven
 Mahidol University
 St. Antonius Ziekenhuis
 University of the Philippines Manila
 Teikyo Academic Research Center
 The University of Hong Kong
 Henry Ford Heart and Vascular Institute
 Maine Research Associates
 Tallinn University of Technology
 Universitatea de Medicina si Farmacie Carol Davila din Bucuresti
 Fudan University
 Brigham and Women's Hospital

Abstract

BACKGROUND: Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A2. METHODS: In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). RESULTS: During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P = 0.20). There were also no significant between-group differences in the rates of the individual components of the primary end point or in all-cause mortality. Darapladib, as compared with placebo, reduced the rate of major coronary events (9.3% vs. 10.3%; hazard ratio, 0.90; 95% CI, 0.82 to 1.00; P = 0.045) and total coronary events (14.6% vs. 16.1%; hazard ratio, 0.91; 95% CI, 0.84 to 0.98; P = 0.02). CONCLUSIONS: In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. Copyright © 2014 Massachusetts Medical Society.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/20.500.14594/34884

Collections

Scopus 2011-2015